Construction and inhibitory effect of MEG3 expression plasmid vector on the proliferation of human pancreatic carcinoma SW1990 cells

doi:10.3760/cma.j.issn.1673-422X.2015.07.003

Abstract

Abstract: ObjectiveTo construct a maternally expressed gene 3 (MEG3) expression plasmid vector, and to obtain MEG3 overexpressed human pancreatic carcinoma SW1990 cells by transfection, and to analyze the effect of MEG3 overexpression on the proliferation of human pancreatic carcinoma SW1990 cells. MethodsA complete gene sequence based on the sequence of MEG3 in the GenBank was designed and inserted into the eukaryotic expression vector pcDNA3.0 to construct recombinant plasmid pcDNA3.0MEG3. It was identified by sequencing and transfected into human pancreatic carcinoma SW1990 cells. The expression of MEG3 in SW1990 cells was confirmed by RTPCR. The effect of MEG3 on proliferation was evaluated by MTT assay. In this study, the SW1990 cells transfected by plasmid pcDNA3.0 were named negative control group, and the usual SW1990 cells were named blank control group. ResultsA MEG3 expression plasmid vectorpcDNA3.0MEG3 was constructed successfully. And pcDNA3.0MEG3 vector was transfected into SW1990 cells successfully. The expression of MEG3 at mRNA in MEG3SW1990 cells increased significantly, about 895 times (F=73.592， P<0.01). The results of MTT assay indicated that overexpressed MEG3 could obviously inhibit SW1990 cells proliferation in vitro. After SW1990 cells transfected with pcDNA3.0MEG3 for 72 hours, the absorbance value was 0.81±0.06, with a statistically significance (F=33.489, P<0.01) compared with negative control group (1.17±0.07) and blank control group (1.08±0.03). ConclusionA MEG3 expression plasmid vectorpcDNA3.0MEG3 is constructed successfully. It is confirmed that MEG3 and its product have obvious inhibitory effects for the proliferation of human pancreatic carcinoma SW1990 cells.

Key words: Pancreatic neoplasms, RNA, Gene expression regulation, Maternally expressed gene 3

Chen Ruidong, Tang Wen, Hu Duanmin. Construction and inhibitory effect of MEG3 expression plasmid vector on the proliferation of human pancreatic carcinoma SW1990 cells[J]. Journal of International Oncology, 2015, 42(7): 488-491.

References

［1］ Gibb EA, Brown CJ, Lam WL. The functional role of long noncoding RNA in human carcinomas［J］. Mol Cancer, 2011, 10: 38. ［2］ Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors［J］. J Clin Endocrinol Metab, 2005, 90(4): 2179-2186. ［3］ Zhang X, Gejman R, Mahta A, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression［J］. Cancer Res, 2010, 70(6): 2350-2358. ［4］ Lu KH, Li W, Liu XH, et al. Long noncoding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression［J］. BMC Cancer, 2013, 13: 461. ［5］ Miyoshi N, Wagatsuma H, Wakana S, et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q［J］. Genes Cells, 2000, 5(3): 211-220. ［6］ Zhang X, Rice K, Wang Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions［J］. Endocrinology, 2010, 151(3): 939-947. ［7］ Zhang X, Zhou Y, Mehta KR, et al. A pituitaryderived MEG3 isoform functions as a growth suppressor in tumor cells［J］. J Clin Endocrinol Metab, 2003, 88(11): 5119-5126. ［8］ Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 noncoding RNA［J］. J Biol Chem, 2007, 282(34): 24731-24742. ［9］ Braconi C, Kogure T, Valeri N, et al. microRNA29 can regulate expression of the long noncoding RNA gene MEG3 in hepatocellular cancer［J］. Oncogene, 2011, 30(47): 4750-4756. ［10］ Wang P, Ren Z, Sun P. Overexpression of the long noncoding RNA MEG3 impairs in vitro glioma cell proliferation［J］. J Cell Biochem, 2012, 113(6): 1868-1874. ［11］ Sun M, Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer［J］. Tumour Biol, 2014, 35(2): 1065-1073. ［12］ Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer［J］. Mol Biosyst, 2013, 9(3): 407-411.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[3]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[4]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[5]	Liu Yang, Jiang Lulu, Guan Kaiwen, Zhou Yueyang, Kang Xiaohong. Role of linc01410 in the occurrence and development of malignant tumors [J]. Journal of International Oncology, 2023, 50(9): 540-543.
[6]	Cui Manli, Lu Ning, Zhu Lin, Li Qian, Zhang Mingxin. Analysis of circRNA in esophageal squamous cell carcinoma based on high-throughput sequencing data [J]. Journal of International Oncology, 2023, 50(6): 328-335.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Bai Ying, Li Qi, Li Yaqin, Zhao Weihong. Role of E2F1 and lncRNAs in the development of malignant tumors [J]. Journal of International Oncology, 2023, 50(3): 164-168.
[9]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[10]	Yan Xuemin, Wu Xiaoyong, Zhang Jiayi, Wen Jinxu, Wang Yuexin. SPRY4-IT1 and breast cancer [J]. Journal of International Oncology, 2023, 50(10): 627-630.
[11]	Zhu Qiwei, Cui Juanjuan, Zhang Zihan, Yang Yanguang, Ge Binbin, Liu Yu, Chu Kaiyue. Cardiac dosimetry analysis and quality of life evaluation of internal breast lymph node irradiation in postoperative left breast cancer [J]. Journal of International Oncology, 2023, 50(1): 17-21.
[12]	Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping. Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma [J]. Journal of International Oncology, 2023, 50(1): 51-54.
[13]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[14]	Zhang Junpeng, Yu Yanyan, Li Baosheng. Mechanism of lncRNA and circRNA regulating the sensitivity of radiotherapy and chemotherapy in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(3): 185-189.
[15]	Yang Wenbo, Xiao Li, Bi Jianqiang, Sun Yunchuan. Application of ¹⁹²Ir brachytherapy combined with external beam radiation and biliary stent in the treatment of unresectable hilar cholangiocarcinoma [J]. Journal of International Oncology, 2022, 49(2): 95-99.